Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.11 USD
Change Today -0.01 / -0.89%
Volume 3.0K
CBMX On Other Exchanges
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

combimatrix corp (CBMX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - $2.16
52 Week Low
08/27/15 - $1.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COMBIMATRIX CORP (CBMX)

Related News

No related news articles were found.

combimatrix corp (CBMX) Related Businessweek News

No Related Businessweek News Found

combimatrix corp (CBMX) Details

CombiMatrix Corporation provides molecular diagnostic solutions and clinical support services. It offers DNA-based testing for the detection of genetic abnormalities. The company develops and markets molecular testing services in areas of miscarriage analysis, prenatal genetics, and postnatal developmental disorders in children. It serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California.

56 Employees
Last Reported Date: 03/17/15
Founded in 1995

combimatrix corp (CBMX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $301.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $255.3K
Compensation as of Fiscal Year 2014.

combimatrix corp (CBMX) Key Developments

CombiMatrix's CombiSNP Array for Prenatal Diagnosis Test Granted Approval From New York State Department of Health

CombiMatrix Corporation announced its SNP-based chromosomal microarray analysis (CMA) test for prenatal diagnosis, the CombiSNP™ Array for Prenatal Diagnosis, has received approval from the New York Department of Health (NYDOH) thus allowing the company to market the test in New York State. CMA uses chorionic villus sampling (CVS) and amniocentesis samples to detect chromosomal imbalances that are not detected by karyotyping. Studies have shown that approximately one in 17 women who have a pregnancy with fetal ultrasound abnormalities and a normal fetal karyotype will have a clinically significant chromosomal abnormality detected by CMA.

CombiMatrix Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

CombiMatrix Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported total revenue of $2,549,000, operating loss of $1,597,000, net loss attributable to common stockholders of $1,612,000 or $0.13 per basic and diluted share against total revenue of $1,941,000, operating loss of $2,689,000, net loss attributable to common stockholders of $2,579,000 or $0.23 per basic and diluted a year ago. The revenue increase in 2015 was driven primarily by higher test volumes, in particular the increase in prenatal microarray testing volumes, as well as by a 27% increase in total billed customers to 224 and higher test volumes from strategic partners. Cash used in operations for the second quarter of 2015 decreased to $1.5 million from $2.4 million for the second quarter of 2014. The reduction was due mainly to lower litigation costs as well as cash reimbursement, which was $2.4 million that Mark mentioned earlier. For the six months, the company reported total revenue of $4,878,000, operating loss of $3,345,000, net loss attributable to common stockholders of $4,267,000 or $0.35 per basic and diluted share against total revenue of $3,763,000, operating loss of $4,674,000, net loss attributable to common stockholders of $4,575,000 or $0.42 per basic and diluted a year ago. Cash used in operations for the first 6 months of 2015 decreased to $2.7 million versus $4 million for the prior 6-month period. The year-to-date decrease was again due primarily to lower litigation costs and cash reimbursement, which increased to $4.6 million from $3.4 million in the comparable period in 2014.

CombiMatrix Corporation to Report Q2, 2015 Results on Aug 05, 2015

CombiMatrix Corporation announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBMX:US $1.11 USD -0.01

CBMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBMX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CBMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COMBIMATRIX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at